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Abstract 
Background: Lower leg ischemia, myopathy, and limb dysfunction are distinguishing features of peripheral artery 
disease (PAD). The myopathy of PAD is characterized by myofiber degeneration in association with extracellular matrix 
expansion, and increased expression of transforming growth factor-beta 1 (TGF-β1; a pro-fibrotic cytokine). In this 
study, we evaluated cellular expression of TGF-β1 in gastrocnemius of control (CTRL) and PAD patients and its relation-
ship to deposited collagen, fibroblast accumulation and limb hemodynamics.
Methods: Gastrocnemius biopsies were collected from PAD patients with claudication (PAD-II; N = 25) and tissue 
loss (PAD-IV; N = 20) and from CTRL patients (N = 20). TGF-β1 in slide-mounted specimens was labeled with fluo-
rescent antibodies and analyzed by quantitative wide-field, fluorescence microscopy. We evaluated co-localization 
of TGF-β1 with vascular smooth muscle cells (SMC) (high molecular weight caldesmon), fibroblasts (TE-7 antigen), 
macrophages (CD163), T cells (CD3) and endothelial cells (CD31). Collagen was stained with Masson Trichrome and 
collagen density was determined by quantitative bright-field microscopy with multi-spectral imaging.
Results: Collagen density increased from CTRL to PAD-II to PAD-IV specimens (all differences p < 0.05) and was 
prominent around microvessels. TGF-β1 expression increased with advancing disease (all differences p < 0.05), cor-
related with collagen density across all specimens (r = 0.864; p < 0.001), associated with fibroblast accumulation, and 
was observed exclusively in SMC. TGF-β1 expression inversely correlated with ankle-brachial index across PAD patients 
(r = −0.698; p < 0.001).
Conclusions: Our findings support a progressive fibrosis in the gastrocnemius of PAD patients that is caused by 
elevated TGF-β1 production in the SMC of microvessels in response to tissue hypoxia.
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Background
Lower leg ischemia, myopathy and limb dysfunction 
are distinguishing features of peripheral artery disease 
(PAD) caused by atherosclerotic blockages of the arter-
ies supplying the legs. This disease affects over 27 million 
people in North America and Europe, where the preva-
lence is estimated to be 16 % of individuals 55 years and 
older, and is associated with a 5-year mortality rate of 
as high as 30  % [1–3]. Overall, about 11 million people 
with PAD are symptomatic [1, 4] and the majority expe-
rience claudication, i.e., walking-induced leg muscle pain 
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of the disease, PAD patients experience foot pain at rest 
(Fontaine Stage III) and non-healing ulcers, necrosis, 
and gangrene in the affected limb (Fontaine Stage IV). 
Hemodynamic changes were thought to be the sole cause 
of these symptoms [5–7]. However, we and others have 
demonstrated that a myopathy exists in the lower legs of 
PAD patients and contributes to limb dysfunction [8–13].
Myopathy in the affected legs of PAD patients is char-
acterized by myofiber degeneration, elevated pro-fibrotic 
cytokines, and increased fibrosis [11, 14–18]. In a recent 
study, we found an average three-fold increase of trans-
forming growth factor-beta 1 (TGF-β1; a potent inducer 
of fibrosis) in homogenates of gastrocnemius biopsies 
from PAD patients compared to controls. TGF-β1 was 
increased in the biopsies of all PAD patients, suggesting 
a chronic pro-fibrotic response [18]. Chronically elevated 
TGF-β1 is known to activate myofibroblasts to deposit 
extracellular matrix around the myofibers and associated 
microvessels which interferes with oxygen and nutri-
ent delivery, producing myofiber degeneration [19–22]. 
Additionally, TGF-β1 can promote PAD myopathy by 
inducing myoblasts to differentiate into myofibroblasts 
rather than new myofibers [19–22].
TGF-β1 may be produced by immune cells and is 
known to induce pathological fibrosis [19, 20, 23], but 
other cells have also been reported to upregulate TGF-
β1 expression and contribute to fibrosis [24–28]. Dur-
ing wound healing, TGF-β1 is released by immune cells 
to initiate the resolution phase of inflammation and to 
activate myofibroblasts to deposit extracellular matrix, 
of which a major component is collagen [29, 30]. It has 
been reported for various vascular diseases, including 
pulmonary arterial hypertension (PAH), that vascular 
smooth muscle cells (SMC) transition from a contractile 
to a synthetic phenotype that produces TGF-β1 [31–33]. 
In PAH, chronic hypoxia induces substantial thicken-
ing of vascular intima, media and adventitia caused by 
extensive proliferation and hypertrophy of vascular SMC 
that exhibit increased expression of TGF-β1, and deposi-
tion of extracellular matrix; features that extend to nor-
mally non-muscularized microvessels [34, 35]. In PAD, 
a similar transitioning of vascular SMC may occur in 
response to exercise-induced ischemia and the chronic 
intermittent hypoxia that are caused by atherosclerosis 
of the large vessels supplying the legs. If that is true, we 
expect this transitioning to also be related to the degree 
of hemodynamic compromise of the affected extremity 
and the clinical stage of PAD. In this study, we evaluated 
the cellular expression of TGF-β1 in the gastrocnemius of 
control and PAD patients with advancing Fontaine Stage, 
and its relationship to collagen deposition, fibroblast 
accumulation, and Ankle-Brachial Index (ABI).
Methods
Human subjects
The experimental protocol was approved by the Institu-
tional Review Boards of the Veterans Affairs Nebraska-
Western Iowa and University of Nebraska Medical 
Centers. All subjects gave informed consent.
PAD groups
We recruited 25 patients with claudication (Fontaine 
Stage II, PAD-II) and 20 patients presenting with tissue 
loss (Fontaine Stage IV, PAD-IV) who were undergo-
ing lower extremity operations for symptomatic PAD. 
The diagnosis for each PAD patient was established 
on the basis of medical history, physical examination, 
decreased ankle brachial index (ABI  <  0.9), and com-
puterized or standard arteriography that revealed 
stenotic and/or occluded arteries supplying the lower 
extremities. PAD-II patients presented with intermit-
tent claudication, but no rest pain or tissue loss. PAD-
IV patients presented with non-healing ulcers and/or 
gangrene.
Control group
We recruited 20 control patients (CTRL) who were 
undergoing lower extremity operations for indications 
other than PAD. Control patients led sedentary lifestyles 
and had no history of PAD symptoms. CTRL patients 
had normal blood flow to their lower limbs as indicated 
by normal lower extremity pulses at examination and 
normal ABI at rest and after stress.
Biopsy
Gastrocnemius samples weighing approximately 250 mg 
were obtained from the anteromedial aspect of the mus-
cle belly, 10  cm distal to the tibial tuberosity. All biop-
sies were obtained with a 6 mm Bergstrom needle. Some 
samples were frozen in liquid nitrogen for biochemi-
cal analysis while others were placed immediately into 
cold methacarn. After 48 h in methacarn, the specimens 




Paraffin-embedded biopsies sectioned at 4 microns were 
stained with a Masson Trichrome Kit according to manu-
facturer’s protocol (Fisher Scientific Richard Allan Sci-
entific #22-110-648, Pittsburg, PA, USA). Briefly, slide 
specimens were deparaffinized in xylene, hydrated and 
then incubated at room temperature in Bouin’s fixative 
for 16 h. Nuclei were stained with Weigert’s Hematoxylin, 
myofiber cytoplasm with Scarlet Red, and collagen with 
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Aniline Blue dye, with washes in-between steps. Stained 
slide specimens were dehydrated and mounted with Per-
mount (Fisher Scientific #SP15-100, Pittsburg, PA, USA).
Image acquisition and spectral analysis
Microscopic fields of the five most fibrotic regions were 
collected from each Masson Trichrome stained slide 
(20× objective). Muscle tissue completely filled each 
chosen microscopic field. Imaging was implemented by 
multispectral wide-field microscopy, using a Leica micro-
scope (North Central Instruments DMRXA2 Model, 
Plymouth, MN, USA) coupled with the Nuance EX 
Multispectral Imaging System (PerkinElmer N-MSI-EX 
Model, Waltham, MA, USA) that incorporates a CCD 
camera and liquid crystal tunable filter. This system gen-
erates an absorbance spectrum at each pixel of a two-
dimensional spatial image of the specimen. The Nuance 
software quantitatively extracts the grey scale image 
of deposited collagen, which is then transferred to the 
Image-Pro® Plus image analysis software (Media Cyber-
netics, Warrendale, PA, USA) for quantification of col-
lagen area and density. Collagen density was determined 
as area-weighted mean pixel intensity (12-bit grey scale). 
Quantitative analysis was performed blinded from the 
group status.
Validation of spectral analysis
Spectral analysis was validated by the hydroxyproline 
assay for collagen content in whole muscle. Total collagen 
content of human gastrocnemius specimens was meas-
ured by a hydroxyproline assay based on a previously 
established protocol for skeletal muscle [36]. To deter-
mine intersession reliability, slide specimens of biopsy 
samples from ten patients were stained by Masson’s Tri-
chrome in two separate analytical sessions and assessed 
by spectral analysis. Detailed methodologies and valida-
tion results can be found in “Additional file 1”.
Quantitative fluorescence microscopy
We describe a novel application of quantitative fluores-
cence microscopy (QFM), a technique developed by our 
laboratory that has previously been validated using mul-
tiple biomarkers of PAD and other diseases, such as pros-
tate cancer [17, 37–41].
Quantitative measurement of TGF‑β1 expression
Duplicate slide specimens of gastrocnemius biopsies 
were exposed to a rabbit anti-TGF-β1 antibody (Abcam 
Ab53169, Cambridge, MA, USA) and a mouse anti-
CD31 antibody (Abcam Ab9498, Cambridge, MA, USA; 
to validate identification of microvessels). Slides were 
then treated with both goat anti-rabbit IgG secondary 
antibody coupled with Alexa Fluor® 555 and goat anti-
mouse IgG secondary antibody conjugated with Alexa 
Fluor® 488 (Life Technologies #A21429  and #A11029, 
Carlsbad, CA, USA). Isotype control slides were 
treated with rabbit IgG (Vector Laboratories #I-1000, 
Burlingame, CA, USA) and mouse IgG1 (eBioscience 
#14-4714-85, San Diego, CA, USA) at the same con-
centration as the anti-TGF-β1 and anti-CD31 antibod-
ies, respectively. For epitope recovery, Tris buffer (pH 
9.0) was used. All labeling procedures were performed 
with a fully programmable, robotic autostainer (Bio-
Genex i6000 Model, Fremont, CA, USA). The labeled 
specimens were mounted in ProLong Gold® anti-fade 
medium containing 4’,6-Diamidino-2-phenylindole 
(DAPI; a nuclear stain) (Life Technologies #P36931, 
Carlsbad, CA, USA). Fluorescence images were cap-
tured with a Leica epifluorescence wide-field micro-
scope (10× objective) (North Central Instruments, 
DMRXA2 Model, Plymouth, MN, USA) and CCD 
camera (Hamamatsu Photonics, Orca C4742 Model, 
Bridgewater, NJ, USA), with Hamamatsu software 
(HCImage 4.0). All fields of each specimen are captured 
and a montage of the gray scale images was generated 
for analysis with Image-Pro® Plus (Media Cybernetics, 
Bethesda, MD, USA). TGF-β1 positive events in the 
microvasculature are partitioned and both event area 
and mean pixel intensity are determined for each (12-bit 
grey scale). The sum of the products of area and mean 
pixel intensity of all positive events per microscopic 
field was computed and normalized to the total area of 
muscle tissue specimen analyzed. Quantitative analysis 
was performed blinded from the group status.
Validation of quantitative fluorescence microscopy
QFM measurements of TGF-β1 were validated by com-
paring results with ELISA and qPCR measurements of 
muscle homogenates from PAD-II and CTRL patients 
(N = 13 in each group). TGF-β1 protein expression was 
measured as part of a customized Human Inflammatory 
Cytokines Multi-Analyte ELISArray Kit (Qiagen, Valen-
cia, CA, USA).
To measure TGF-β1 gene transcripts in skeletal mus-
cle biopsies, RNA extraction, reverse transcription reac-
tions, and qPCR were performed as previously described 
[40, 42] and levels were normalized to myosin gene tran-
scripts. Intrasession reliability was determined by com-
paring the TGF-β1 measurement of each slide from the 
mean of its duplicate pair. Intersession reliability was 
determined from the averages of patient biopsy speci-
mens, analyzed a second time in the next analytical ses-
sion. Detailed methodologies and validation results can 
be found in “Additional file 1”.
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Co‑localization of TGF‑β1 and Ki‑67 to candidate cells 
by immunofluorescence
Individual slides were treated with primary anti-TGF-β1 
antibody (Abcam Ab53169, Cambridge, MA, USA) and 
primary antibody specific for each of the following cell 
types. For endothelia, we used an antibody against CD31 
(1:50 dilution) (Abcam Ab9498, Cambridge, MA, USA); 
for vascular smooth muscle cells, an antibody against 
high molecular weight caldesmon (1 ug/mL) (Abcam 
Ab1826, Cambridge, MA, USA); for fibroblasts, an anti-
body for TE-7 (1:10 dilution) (Millipore CBL271, Biller-
ica, MA, USA); for macrophages, antibodies for CD163 
(2.5 ug/mL) (Abcam Ab156769, Cambridge MA, USA) 
and CD68 (1 ug/mL) (Fisher Scientific Thermo MS-397, 
Pittsburg, PA, USA); for T cells, an antibody for CD3 
(1ug/mL) (Abcam Ab699, Cambridge, MA, USA). To 
detect proliferative cells, we labeled with an antibody 
against Ki-67 (5 ug/mL) (Abcam Ab15580, Cambridge, 
MA, USA) and ProLong Gold® anti-fade medium with 
DAPI nuclear stain (Life Technologies #P36931, Carls-
bad, CA, USA). For all labels, we used Tris buffer (pH 
9.0) for epitope recovery, except for Ki-67 where we 
used citrate buffer (pH 6.0). Isotype control slides were 
stained with rabbit IgG (Vector Laboratories #I-1000, 
Burlingame, CA, USA) or mouse IgG1 (eBioscience #14-
4714-85, San Diego, CA, USA), IgG2a (eBioscience #14-
4724-85, San Diego, CA, USA), or IgG2b (eBioscience 
#14-4732-85, San Diego, CA, USA) at the same concen-
tration as their respective primary antibodies. Primary 
antibodies to TGF-β1 and Ki-67 were labeled with a goat 
anti-rabbit IgG secondary antibody coupled with Alexa 
Fluor® 555 (Life Technologies #A21429, Carlsbad, CA, 
USA) and all other primary antibodies were labeled with 
a goat anti-mouse IgG secondary antibody coupled with 
Alexa Fluor® 647 (Life Technologies #A21236, Carlsbad, 
CA, USA). All labeling procedures were performed with 
a fully programmable, robotic autostainer (BioGenex 
i6000 Model, Fremont, CA, USA).
Detection of fibroblast accumulation 
by immunohistochemistry
Duplicate slide specimens were deparaffinized and 
heated in Tris buffer (pH 9.0) for epitope recovery. Speci-
mens were blocked with 10  % goat serum for 5  min, 
treated with primary antibody against TE-7 (1:10 dilu-
tion) (Millipore CBL271, Billerica, MA, USA), a highly 
specific marker of fibroblasts [43–45], and then incu-
bated overnight for 14 h. An isotype control treated with 
the same concentration of mouse IgG1 (EBioscience #14-
4714-85, San Diego, CA, USA) was included with each 
duplicate antibody-treated slide. Specimens were treated 
with peroxidase-conjugated secondary antibody accord-
ing to instructions from the DAB Polink 2 Kit (GBI Labs 
#D22-60D, Bothell, WA, USA). Hematoxylin (Fisher Sci-
entific Richard Allan Scientific #72511, Pittsburg, PA, 
USA) was used as the counterstain for 4 min. Slides were 
dehydrated and mounted in Permount (Fisher Scientific 
#SP15-100, Pittsburg, PA, USA). Staining was imple-
mented with a fully programmable, robotic autostainer 
(BioGenex i6000 Model, Fremont, CA, USA).
Statistical analyses
The baseline characteristics between PAD and controls 
subjects were compared using general linear models for 
continuous variables and Chi square tests for categorical 
variables to determine confounders. Confounding vari-
ables were covariates in subsequent analyses. For all bio-
logical parameters, group differences were determined by 
analysis of covariance (ANCOVA) and evaluated post-
hoc by Bonferroni adjusted t tests. Correlations were 
assessed by the Pearson test. All statistical analyses were 
performed with SPSS 20 (IBM, Armonk, NY, USA) using 
a confidence level of 95 %.
Results
Patient demographics
Data for CTRL, PAD-II, and PAD-IV patients are pre-
sented in Table  1. On average, PAD-IV patients were 
6 years older than PAD-II (p = 0.047) and 8 years older 
than CTRL (p = 0.006) patients. More PAD-IV patients 
had diabetes than PAD-II and CTRL patients (χ2 = 5.55, 
p = 0.006; both p < 0.05). Age and diabetes were treated 
as covariates in all subsequent analyses.
PAD gastrocnemius specimens exhibited increased 
collagen deposition with advancing disease stage
Spectral imaging revealed increased collagen density 
with higher Fontaine stage, which became diffuse in 
Stage IV muscle (Fig.  1a). Collagen density and area in 
PAD muscle was increased between the myofibers and 
around the lumen of microvessels. The most noticeable 
pathological change was dense collagenous investment of 
the microvessels of PAD muscle (arrows). Spectral analy-
sis established increased collagen density (p < 0.001) and 
area (p  <  0.001) at the higher Fontaine stage. Collagen 
density in the PAD-IV patients (2708.8 ± 612.3 gsu) was 
40 and 75 % greater than in PAD-II and CTRL patients, 
respectively (1969.9  ±  277.5 and 1551.7  ±  232.8  gsu; 
both p < 0.001), while collagen density was 25 % greater 
in PAD-II compared to CTRL (p = 0.015) (Fig. 1b). Col-
lagen area was approximately twice as great in PAD-IV 
(241,179  ±  133,159  mm2) compared to either PAD-II 
or CTRL gastrocnemius (109,179  ±  56,481  mm2 and 
118,624 ± 99,559 mm2; both p < 0.01), with no difference 
between PAD-II and CTRL (Fig. 1c). These data suggest 
that increased collagen deposition occurs first around 
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microvessels and then expands throughout the extracel-
lular matrix between myofibers and myofascicles as PAD 
advances.
TGF‑β1 expression is tightly linked to myofibrosis of PAD 
gastrocnemius
QFM imaging localized TGF-β1 expression to the vas-
culature of both CTRL and PAD muscle, with no detect-
able labeling outside of the vascular walls (Fig.  2a). 
TGF-β1 expression was uniformly low in CTRL muscle 
and exhibited a progressive increase in PAD-II and PAD-
IV muscle. PAD-IV gastrocnemius had approximately 
2.5- and 8-fold greater expression of TGF-β1 compared 
to PAD-II and CTRL patients (6.56 ± 3.12 vs. 2.89 ± 2.12 
and 0.842 ± 0.399 gsu, respectively; both p < 0.001), while 
PAD-II had 3.5-fold more TGF-β1 than CTRL (p < 0.05; 
Fig.  2b). Vascular TGF-β1 expression positively corre-
lated with collagen density across all subjects (N = 65) in 
this study (r = 0.798, p < 0.001; Fig. 2c). Separate analysis 
of the PAD patients alone (PAD-II and PAD-IV; N = 45) 
and the CTRL subjects alone (N = 20) revealed a signifi-
cant correlation between TGF-β1 and collagen density 
in the PAD group (r = 0.854, p < 0.001), but not in the 
CTRL group (r =  0.119, p =  0.618), indicating that the 
pathological fibrosis in PAD is driven by TGF-β1 expres-
sion. Across all subjects (N  =  65) in this study, vascu-
lar TGF-β1 expression increased with decreasing ABI 
(r = −0.694, p < 0.001; Fig. 2d), which is an indicator of 
blood flow (hemodynamic) compromise and increased 
ischemia of the lower limbs. The relationship between 
TGF-β1 and ABI remained significant when analyzing 
PAD patients alone (r = −0.543, p < 0.001). These find-
ings identify increased microvascular TGF-β1 expression 
as a characteristic of PAD muscle and establish an associ-
ation between increased TGF-β1 expression and muscle 
fibrosis and between increased TGF-β1 expression and 
advancing disease stage. Additionally, they show that as 
the blood flow (and presumably oxygenation) to the leg 
is decreased by atherosclerotic blockages in the arteries 
supplying the legs (reflected by decreasing ABI) there 
is a corresponding increase in the expression of TGF-
β1 expression in the microvessels of the muscles of the 
affected leg.
Increased expression of TGF‑β1 is associated 
with accumulation of fibroblasts and collagen deposition 
in PAD gastrocnemius
To further evaluate the concept of a TGF-β1 dependent 
myofibrosis in PAD, we selected three adjacent gastroc-
nemius sections and stained the first section for collagen 
with Masson Trichrome, the second for TE-7 positive 
fibroblasts by immunohistochemistry, and the third for 
TGF-β1 by immunofluorescence. Images from a PAD-
IV patient with significant fibrosis are shown in Fig.  3. 
Table 1 Demographics of study groups
CTRL Control subject, PAD-II PAD patient at Fontaine Stage II, PAD-IV PAD patient at Fontaine Stage IV
* p < 0.05 compared to each of the other two groups by post-hoc Bonferroni adjusted t tests
a Obesity: Body mass index >30
b Renal insufficiency: Creatinine clearance <60 ml/min/1.73m2
c ABI: data presented as mean ± standard deviation
CTRL PAD‑II PAD‑IV p value
Number of patients 20 25 20 N/A
Mean age (years) 62.1 ± 5.40 64.1 ± 7.80 69.9 ± 9.40* 0.011
Gender (male/female) 19/1 24/1 20/0 0.983
Height (m) 1.75 ± 0.07 1.76 ± 0.06 1.77 ± 0.06 0.576
Weight (kg) 91.0 ± 17.4 87.5 ± 18.8 85.0 ± 21.1 0.598
Body mass index 29.9 ± 6.40 28.2 ± 5.16 28.4 ± 6.61 0.593
Obesitya (%) 45 36 25 0.416
Smoking (%) 50.0 56.0 30.0 0.202
Diabetes Mellitus (%) 25.0 20.0 65.0* 0.004
Dyslipidemia (%) 55.0 80.0 60.0 0.166
Coronary artery disease (%) 20.0 36.0 35.0 0.701
Myocardial infraction (%) 0.00 8.00 0.00 0.192
Hypertension (%) 65.0 84.0 90.0 0.116
Statins Medication (%) 70.0 84.0 65.0 0.317
Renal insufficiencyb (%) 5.00 12.0 20.0 0.352
Ankle Brachial Indexc (minimum–maximum) 1.04 ± 0.11* (0.79–1.20) 0.55 ± 0.22* (0.10–0.95) 0.22 ± 0.13* (0.00–0.44) <0.001
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In areas of dense collagen deposition (ellipse, Fig. 3a), we 
observed a high density of fibroblasts (ellipse, Fig.  3b). 
This is in contrast to areas containing relatively little col-
lagen (circle, Fig. 3a), which had very few fibroblasts (cir-
cle, Fig. 3b). Vessels near the heavily fibrotic areas (high 
magnification of the square in Fig.  3a) contain a high 
density of fibroblasts (Fig. 3c) in association with intense 
TGF-β1 labeling (Fig. 3d) and dense adventitial collagen 
(square, Fig. 3a). These observations are consistent with 
the pro-fibrotic activity of TGF-β1, where TGF-β1 acti-
vates motile fibroblasts that deposit collagen (29, 30), 
and establish a spatial association of increased TGF-
β1 expression, fibroblast accumulation, and collagen 
deposition as a characteristic of PAD pathophysiology. 
They also further demonstrate that the microvessels of 
ischemic legs play a key role in the pathophysiology of 
PAD myofibrosis.
TGF‑β1 is expressed by vascular smooth muscle cells in the 
microvessels of PAD gastrocnemius
To determine the specific cellular source of TGF-β1 
expression in the microvessels of PAD gastrocnemius, we 
implemented co-localization studies with antibodies for 
highly specific markers of candidate vascular cells, includ-
ing endothelial cells, SMC, fibroblasts, macrophages, and 
T cells (Fig. 4). TGF-β1 labeling did not co-localize with 
CD163 positive macrophages (Fig.  4a), CD3 positive T 
cells (Fig. 4b), or CD31 positive endothelia (Fig. 4c). TE-7 
Fig. 1 Collagen deposition in the gastrocnemius of CTRL and PAD patients with claudication and tissue loss. a Representative greyscale images 
of gastrocnemius specimens stained with Masson Trichrome were captured by multi-spectral, bright-field microscopy (20× objective). Specimens 
were collected from control subjects (CTRL) and PAD patients at Fontaine Stage II (claudication, PAD-II) and Stage IV (tissue loss, PAD-IV) disease. 
Myofibers delineated by collagen staining, appear black. Collagen density and area are represented by the intensity and extent of the bright pixels, 
respectively. Arrows point to collagen deposition associated with microvessels. b Collagen density and c collagen area in specimens of CTRL 
(n = 20), PAD-II (n = 25), and PAD-IV (n = 20) gastrocnemius were analyzed by quantitative multi-spectral microscopy. Collagen density was calcu-
lated as area-weighted mean intensity of all collagen events per specimen. Data are presented as mean ± standard error of the mean. Significance 
denoted as *p < 0.05; **p < 0.01; ***p < 0.001
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Fig. 2 TGF-β1 expression in CTRL and PAD gastrocnemius and its relationship with collagen density and ABI. a Representative greyscale images of 
gastrocnemius microvessels positive for TGF-β1 labeling (arrows) were captured with a wide-field fluorescence microscope (10× objective). Unla-
beled myofibers (blue line) appear grey against black background. Specimens collected from control subjects (CTRL) and PAD patients at Fontaine 
Stage II (claudication, PAD-II) and Stage IV (tissue loss, PAD-IV) disease were labeled with primary antibody specific for TGF-β1 and a fluorescent 
secondary antibody. Both the intensity and extent of TGF-β1 labeling were increased in the microvessels of PAD versus CTRL and PAD-IV versus 
PAD-II specimens. b TGF-β1 expression was determined by quantitative fluorescence microscopy and defined as the sum of the products of area 
and mean pixel intensity of all positive events per microscopic field, normalized to the total area of specimen in the same field. The relationships 
between normalized TGF-β1 expression and collagen density (c), and Ankle-Brachial Index (d) were determined by the Pearson correlation analysis. 
Data are presented as mean ± standard error of the mean and significance is denoted as *p < 0.05; **p < 0.01; ***p < 0.001
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positive fibroblasts located in the adventitia were not 
positive for TGF-β1, nor were cells stained with TE-7 in 
the intima, which may represent endothelial-mesenchy-
mal transition (Fig.  4d). TGF-β1 co-localized with cells 
expressing high molecular weight caldesmon, a marker 
of SMC that is not found in macrophages or fibroblasts 
[46, 47] (Fig. 4e). Prominent co-localization was observed 
in rhomboidal-shaped SMC located in the subendothelial 
region (arrows). This has been reported for other vascu-
lar fibrotic pathologies, where SMC are activated toward 
the pro-fibrotic synthetic phenotype, including in ath-
erosclerotic arterial plaques. Many of the rhomboidal 
SMC stained positive for Ki-67 in the nuclei (arrowheads; 
Fig.  4f ), indicating they are proliferative and activated. 
The finding that TGF-β1 is derived from locally prolifera-
tive SMC rather than immune cells in PAD myofibrosis is 
novel.
Discussion
This study established that vascular TGF-β1 is strongly 
associated with myofibrosis during the progression of 
PAD. Using rigorous quantitative methods, we have 
shown that vascular expression of TGF-β1 and collagen 
deposition in PAD gastrocnemius increased in paral-
lel with advancing disease severity. Qualitatively, TGF-
β1 production was limited to cells in the walls of the 
microvessels in affected PAD muscle. In advanced dis-
ease, these cells expressing TGF-β1 were present at high 
density and were associated with accumulation of fibro-
blasts and increased deposition of collagen around the 
vessels and throughout an expanded interstitium. Our 
findings suggest that increased vascular TGF-β1 induces 
PAD myofibrosis by activating fibroblasts that prolif-
erate and either stay locally around the microvessels or 
migrate between myofibers and around myofascicles into 
Fig. 3 Association of TGF-β1 expression with fibroblast accumulation and collagen deposition in gastrocnemius of PAD patients. All images are of 
the gastrocnemius of a representative PAD patient who presented with tissue loss. a Masson Trichrome staining reveals highly fibrotic regions (blue 
labeling) around myofibers (oval) and microvessels (rectangle), and a region with relatively little fibrosis (circle). b A neighboring 4-micron section 
was labeled by immunohistochemistry with anti-TE-7 antibody, a fibroblast marker which identified fibroblasts in the same three regions of interest. 
c High magnification of the rectangular region of interest reveals the extent of fibroblast accumulation with microvessels. d A neighboring section 
labeled by immunofluorescence for TGF-β1 (green fluorescence) shows the intensity and extent of TGF-β1 labeling of microvessels within the rectan-
gular region of interest. Wheat Germ Agglutinin (WGA; red fluorescence) labeled membranes and was used to delineate myofibers
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Fig. 4 Evaluation of candidate vascular cells for TGF-β1 expression. All immunofluorescence images are from PAD patients who present with tissue 
loss and are representative of all diseased patients in our study. a TGF-β1 labeling (green) does not co-localize with CD163 positive macrophages 
(red) present at relatively high density in the adventitia of microvessels. High magnification of the boxed region reveals cellular labeling of CD163 
around DAPI stained nuclei (blue). b TGF-β1 labeling (green) does not co-localize with CD3 positive T cells (red) that are located typically around 
myofibers near microvessels. High magnification of the boxed region reveals cellular labeling of CD3 around DAPI stained nuclei (blue). c TGF-β1 
labeling (green) does not co-localize with CD31 positive endothelial cells (red) that are characteristically located in the intima of microvessels. d 
TGF-β1 labeling (green) does not co-localize with TE-7 positive fibroblasts (red). e TGF-β1 labeling (green) co-localizes with high molecular weight 
caldesmon (h-Caldesmon) a specific marker of smooth muscle cells (red). Arrows point to rhomboidal morphology characteristic of secretory SMC. f 
The proliferation marker Ki-67 (green) is expressed in nuclei (blue) of h-Caldesmon positive SMC (red) that highly express TGF-β1 as determined with 
a neighboring tissue section
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areas of myofiber degeneration, thus being responsible 
for the perivascular and endomysial/perimysial fibro-
sis we and others [48, 49] have shown in the affected leg 
muscles of PAD patients. Accumulation of fibrous tissue 
in the PAD muscle can affect the muscle both by com-
promising the function of its myofibers and myofascicles 
but also by interfering with the function of its microves-
sels. The fibrosis of microvessels in PAD muscle has been 
shown by us and others [48, 49] to involve both collagen-
ous thickening of the capillaries and muscularization and 
fibrosis of normally non-muscularized microvessels and 
is known to impair diffusion of gases and small molecules 
between the vasculature and end organ parenchyma, 
probably enhancing the tissue hypoxia and inducing 
myofiber degeneration in the affected PAD legs. TGF-β1 
may also be contributing to PAD myopathy by suppress-
ing skeletal muscle regeneration by inducing myoblasts to 
differentiate into myofibroblasts rather than new myofib-
ers [21, 22]. This model of PAD myofibrosis is consistent 
with the contribution of TGF-β1 to fibrosis and muscle 
degeneration seen in other skeletal myopathies [19] and 
myocardiopathies [50, 51].
Another novel finding of this study is that TGF-β1 is 
expressed exclusively by vascular SMC in PAD mus-
cle. Our co-localization studies show conclusively that 
TGF-β1 is produced by vascular SMC and not in the 
associated fibroblasts, suggesting that these fibroblasts 
are activated by TGF-β1 produced in the SMC. These 
observations again point to a widely reported mechanism 
of fibrosis in human fibrotic diseases, in which TGF-β1 
activates fibroblasts to myofibroblasts. Our co-localiza-
tion studies also revealed that macrophages and T cells, 
which are reported to be the source of TGF-β1 in other 
skeletal myofibroses, did not express detectable TGF-β1 
in PAD muscle [19, 20]. This is likely due to the differ-
ent etiology of PAD myofibrosis compared to other skel-
etal myopathies, of which the muscular dystrophies are 
the best studied. The primary cause of PAD myopathy 
is atherosclerotic stenoses and occlusions of large arter-
ies that supply the legs, which produce ischemia and 
hypoxia in the lower extremities [4]. Over time, chronic 
hypoxia may damage the muscle myofibers to produce 
their characteristic degeneration and induce SMC of the 
microvessels to increase TGF-β1 expression and cause 
myofibrosis. In contrast, muscular dystrophies origi-
nate from mutated genes that code for defective skel-
etal muscle proteins primarily involved in transmitting 
sarcomeric forces to the extracellular matrix [19, 20]. In 
muscular dystrophies, repeated cycles of myofiber degen-
eration and regeneration induce a chronic inflammatory 
response that includes TGF-β1 production by activated 
immune cells and produces the myofibrosis. Progressive 
fibrosis in PAD muscle appears not to be a response to 
chronic inflammation. We have profiled cytokines in the 
gastrocnemius of moderately diseased PAD patients and, 
indeed, did not find a generalized inflammatory signature 
[18]. The unique cytokine milieu produced by chronic 
ischemia in PAD gastrocnemius may explain why we 
did not observe detectable TGF-β1 in macrophages and 
T cells as is seen, e.g., in muscular dystrophies. Overall, 
the vascular etiology of PAD myofibrosis points to the 
possibility that chronic hypoxia of microvessels causes 
increased expression of TGF-β1 by SMC.
In PAD, hypoxic injury may cause transitioning of 
SMC from a contractile to a synthetic phenotype that 
is pro-fibrotic. Vascular SMC are normally contractile, 
with a spindle-shaped morphology and an abundance 
of contractile proteins that allow them to regulate vessel 
diameter. Under various pathological conditions marked 
by hypoxia, SMC can acquire a synthetic phenotype 
marked by rhomboidal morphology, decreased contrac-
tile proteins, and the ability to proliferate, migrate, and 
deposit collagen [31, 32]. In this study, we found that 
patients with lower ABI had greater expression of TGF-
β1 across Fontaine Stages of disease, which suggests that 
hypoxia induces SMC to increase TGF-β1 expression. 
This is supported by our observation that many SMC 
with increased TGF-β1 expression were proliferative and 
exhibited a rhomboidal morphology that is characteristic 
of synthetic SMC.
The responses of vascular SMC to hypoxia in the 
ischemic muscle of PAD patients are likely similar to 
those in pulmonary arterial hypertension (PAH) and may 
provide insight into the mechanisms by which TGF-β1 
expression is increased in PAD muscle. PAH is a condi-
tion characterized by substantial thickening of the vas-
cular wall caused by extensive proliferation of SMC that 
exhibit increased TGF-β1 expression and deposition of 
collagen [34, 35]. Hypoxia alone can stimulate prolifera-
tion of human pulmonary SMC in culture [34]. Alterna-
tively, growth factors released by cultured endothelial 
cells exposed to hypoxia also can stimulate proliferation 
of SMC [52]. Either or both mechanisms may operate 
in  vivo causing SMC to shift towards a more prolifera-
tive, synthetic phenotype in PAH. In PAD gastrocnemius, 
SMC with intense TGF-β1 labeling were observed fre-
quently in the sub-endothelial region, suggesting that 
hypoxic insult to endothelial cells may stimulate secre-
tion of growth factors that cause SMC to increase TGF-
β1 expression. Given the histopathological similarities 
between PAH and PAD, future mechanistic studies of 
PAD myofibrosis should determine whether chronic 
hypoxia directly induces TGF-β1 expression by SMC, 
and/or activates endothelial cells to increase production 
of pro-fibrotic factors that cause SMC to increase expres-
sion of TGF-β1.
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Understanding the mechanism by which chronic 
hypoxia stimulates SMC production of TGF-β1 can lead 
to development of animal models that recapitulate the 
myofibrosis observed in patients with PAD. Such mod-
els will allow for testing of novel anti-fibrotic therapies 
that modulate the cellular phenotypes and growth factors 
released from specific cell types to reduce SMC expres-
sion of TGF-β1 and myofibrosis. Importantly, we can 
determine side effects in these animals that may hamper 
the success of therapeutic strategies. Additionally, limb 
function can be assessed over time and in relation to 
changes in myofibrosis.
A limitation of this study is the number of human sub-
jects, however our power calculations indicated enough 
statistical power to analyze each of the biological param-
eters. The main barriers against recruitment of additional 
human subjects are the rigorous inclusion and exclu-
sion criteria used to reduce confounding variables, and 
the demands of obtaining muscle biopsies. PAD patients 
included in our study must have had exercise-limiting 
claudication established by history and direct observa-
tion during a screening walk test administered by a vas-
cular surgeon. We enrolled only those patients who did 
not exhibit concurrent symptoms of heart, lung, mus-
culoskeletal (mainly arthritis), and neurologic (mainly 
back pain and sciatica) ailments that would affect their 
walking ability and their performance in the screening 
walk test. Furthermore, we excluded individuals with (1) 
asymptomatic PAD, i.e., patients with occlusive arterial 
disease who do not have claudication symptoms or tissue 
loss/gangrene, (2) acute lower extremity ischemic events 
secondary to thromboembolic disease or acute trauma, 
and (3) exercise capacity limited by conditions other than 
claudication including leg (joint or musculoskeletal and 
neurologic) and systemic (heart and lung disease) pathol-
ogy. The invasiveness of a muscle biopsy and the time 
required often discourages participation of PAD patients 
and control subjects especially when the muscle biopsy 
cannot be performed during their routine care (at the 
time of a leg operation) which was frequently the case for 
most PAD-II and control patients. With the 65 patients 
recruited, post-hoc power sample analysis using the data 
(mean and SD) for collagen density and area, and TGF-
β1 expression, revealed adequate statistical power. Power 
sample analysis for an ANCOVA of TGF-β1 expression 
demonstrated that a total sample size of N = 65 (20, 25 
and 20 subjects per group) assured at least 99  % power 
to detect differences between groups adjusting for two 
covariates with a conservative R2 value of 0.20. Similarly, 
for an ANCOVA of collagen density and area, our sam-
ple size assured at least 99 and 93 % power, respectively, 
to detect differences between the groups adjusting for 
two covariates with a conservative R2 value of 0.20. The 
power and sample size determination package PASS 
(PASS, Number Cruncher Statistical Systems, Kaysville, 
UT) was used for the analysis.
An additional limitation is the correlational nature 
of the study, but the high quality human data that we 
have presented for PAD myofibrosis provide a basis for 
future mechanistic studies, development of disease mod-
els, and improved therapies and prognosis. In this study, 
we established an association between ischemia and 
increased TGF-β1 production by microvascular SMC. 
We have identified microvascular SMC in PAD muscle 
as the exclusive producer of TGF-β1, making it a spe-
cific target for anti-fibrotic therapies for PAD. Candidate 
therapeutic drugs will be those capable of shifting the 
pro-fibrotic synthetic phenotype of SMC back to the con-
tractile form to decrease TGF-β1 expression and prevent 
or slow down the progression of PAD myofibrosis. More-
over, TGF-β1 production by SMC may be a potential 
biomarker for determining the efficacy of therapeutics, 
including anti-fibrotic interventions. Finally, our finding 
of the progressive worsening of myofibrosis with advanc-
ing Fontaine Stage in PAD suggests that the patients who 
are optimal for anti-fibrotic intervention are those with 
moderate disease, since (1) a relatively small propor-
tion of vascular SMC express TGF-β1, (2) fibroblasts are 
present at a relatively low density, and (3) collagen dep-
osition is largely limited to microvessels with little expan-
sion into the interstitium.
Conclusions
Fibrosis is often viewed as an adaptive response to 
injury and tissue degeneration, but as we have shown in 
this study, can be part of the pathophysiology of chronic 
disease. We have established that increased expres-
sion of TGF-β1 by microvascular SMC in the gastroc-
nemius of PAD patients correlates with Fontaine Stage 
and increasing collagen deposition. The pattern of vas-
cular TGF-β1 expression, fibroblast accumulation, and 
collagen deposition points to pathological changes in 
microvessels as the immediate cause of PAD myofi-
brosis. The contribution of hypoxia was suggested by a 
strong negative correlation between ABI and vascular 
TGF-β1 expression and presence of locally prolifera-
tive rhomboidal SMC in microvessels of PAD gastroc-
nemius that are indicative of the pro-fibrotic synthetic 
phenotype of SMC known to be induced by hypoxia. 
Collectively, these findings provide insight into the 
development of PAD myofibrosis and direction for 
future mechanistic studies, and consequently, a basis 
for improved diagnosis and treatment for patients with 
PAD.
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